MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Rigel Pharmaceuticals Net Income 2011-2026 | RIGL
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Rigel Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.5 M | -25.1 M | -58.6 M | -17.9 M | -29.7 M | -66.9 M | -70.5 M | -78 M | -69.2 M | -51.5 M | -90.9 M | -89 M | -98.8 M | -86 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.5 M | -98.8 M | -58.2 M |
Quarterly Net Income Rigel Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.9 M | 59.6 M | 11.4 M | 12.4 M | -1.03 M | -8.25 M | -5.69 M | -6.6 M | -13.5 M | - | -19 M | -13.5 M | -27.4 M | - | -21 M | -13.8 M | 39.5 M | -19.2 M | -14.2 M | 3.67 M | 21.2 M | -17.2 M | -49.7 M | -38.2 M | -17.6 M | 3.23 M | -73.7 M | -49.9 M | -24.4 M | -25.9 M | -52.1 M | -34.5 M | -15.3 M | -15.6 M | -53.6 M | -31 M | -17.5 M | -12.7 M | -6.67 M | -13.9 M | -18.2 M | -22.3 M | -20.9 M | -25.4 M | -22.3 M | -16.9 M | -23.8 M | -22.8 M | -25.6 M | -25.5 M | -25.5 M | -24.7 M | -23.2 M | -25.8 M | -17.9 M | -21.5 M | -20.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 59.6 M | -73.7 M | -16.7 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
22.4 M | $ 20.36 | -1.64 % | $ 2.57 B | USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 0.81 | -3.83 % | $ 4.42 M | China |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 164.62 | -1.06 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
172 M | $ 8.57 | -1.95 % | $ 1.39 B | Britain |
 |
Certara
CERT
|
-1.6 M | $ 7.27 | 3.05 % | $ 1.17 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
214 M | $ 23.94 | 0.23 % | $ 2.93 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-27 M | $ 18.1 | 1.17 % | $ 869 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Eton Pharmaceuticals
ETON
|
-936 K | $ 17.89 | -1.43 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
783 M | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-22.3 M | $ 26.27 | -2.2 % | $ 703 M | USA |
 |
Galapagos NV
GLPG
|
-103 M | $ 33.2 | -2.61 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-15.8 M | $ 27.98 | 2.15 % | $ 364 M | USA |
 |
Galecto
GLTO
|
-38.3 M | $ 29.63 | -1.39 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
4.76 B | $ 27.76 | -6.37 % | $ 17.6 B | Danmark |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-65.3 M | $ 1.0 | -1.47 % | $ 73.4 M | USA |
 |
Halozyme Therapeutics
HALO
|
317 M | $ 69.4 | -0.64 % | $ 8.32 B | USA |
 |
Hoth Therapeutics
HOTH
|
-8.19 M | $ 1.01 | -0.98 % | $ 6.44 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
Harmony Biosciences Holdings
HRMY
|
159 M | $ 28.63 | -0.95 % | $ 1.65 B | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
-2.16 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Immuron Limited
IMRN
|
-2.85 M | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
|
Immatics N.V.
IMTX
|
-93.3 M | $ 9.95 | -0.4 % | $ 626 M | Germany |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Immunic
IMUX
|
-97.2 M | $ 1.12 | 5.19 % | $ 174 M | USA |
 |
Agenus
AGEN
|
-257 M | $ 3.24 | -3.14 % | $ 1.16 M | USA |
 |
Immunovant
IMVT
|
-414 M | $ 27.24 | -1.84 % | $ 4.13 B | USA |
 |
Inhibrx
INBX
|
-241 M | $ 76.35 | -1.47 % | $ 3.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M |  Israel |
 |
InMed Pharmaceuticals
INM
|
-7.95 M | $ 0.78 | -4.88 % | $ 1.91 M | Canada |
 |
INmune Bio
INMB
|
-30 M | $ 1.39 | 4.66 % | $ 25 M | USA |
 |
Insmed Incorporated
INSM
|
-1.28 B | $ 147.23 | 0.62 % | $ 29.3 B | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |